Adverse Event Reporting

VAERS ID	1509069
Gender	Unknown
Age
StateCode	TX
Pharmaceutical Company	PFIZER\BIONTECH
Lot Number	EN6207
Number of vaccinations	1
Vaccinated	2021-03-07
Onset	2021-03-10
Condition	Permanent Disability

Symptoms

• Blood test
• Musculoskeletal stiffness
• Prostatic specific antigen

Current Illness

Carpal tunnel release (Physiotherapy)

Preexisting Conditions

Other Medications

ANGIOTROFIN; SECOTEX OCAS

Previous Vaccinations

Allergies

Laboratory Data

Test Date: 20210510; Test Name: Blood test; Result Unstructured Data: Test Result:104; Comments: Glucose; Test Date: 20210617; Test Name: Blood test; Result Unstructured Data: Test Result:97; Comments: After treatment; Test Date: 20210510; Test Name: Prostatic Antigen; Result Unstructured Data: Test Result:7.
75; Comments: Before 8.
66

Write-up

Severe legs muscular stiffness; This is a spontaneous report from a contactable consumer (patient).
This 63-year-old patient of an unspecified gender received first dose of bnt162b2 (BNT162B2), via an unspecified route of administration, administered in left arm on 07Mar2021 11:00 (Batch/Lot Number: EN 6207) as dose 1, single for covid-19 immunisation.
Medical history included Inflamation carpal tunnel 2020 and ongoing (Physiotherapy).
Concomitant medication(s) included diltiazem hydrochloride (ANGIOTROFIN) taken for high blood pressure from Jan2020 and ongoing; tamsulosin hydrochloride (SECOTEX OCAS) taken as prostrate treat from Feb2021 to Apr2021.
The patient experienced severe legs muscular stiffness on 10Mar2021.
Relevant tests: blood test on10May2021: glucose prostatic antigen units: 104, 7.
75 (Norm low: 55, <4, Norm high: 99), Comments: before 8,66; blood test on 17Jun2021: glucose prostatic antigen units: 97 (Norm low: 55, Norm high: 99), Comments: After treatment on treatment.
patient received treatment for the event.
The outcome of event was not recovered.
Event considered serious due to disability/incapacity.
No follow-up attempts are needed.
No further information is expected.